Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,734 across all filing types
Latest filing 2021-08-31 Regulatory Filings
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
本公司受邀參加統一證券舉辦之線上投資論壇
Regulatory Filings Classification · 90% confidence The document is a short announcement (640 characters) about the company participating in an online investor forum organized by a securities firm. It mentions the date and time of the event and that the company will explain its financial and operational status to institutional investors. There is no detailed financial data or comprehensive report content. The document serves as a notice of an upcoming investor presentation rather than the presentation itself or a detailed report. Therefore, it fits best as an Investor Presentation (IP) announcement or related notice. However, since it is only an announcement of participation and not the presentation material itself, and given the short length, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a general regulatory announcement about an event, not the actual presentation or report.
2021-08-31 Chinese
公告本公司110年股東常會決議解除董事競業禁止之限制
Board/Management Information Classification · 95% confidence The document is a regulatory announcement from a listed company (1795 美時) regarding a shareholder meeting resolution to lift restrictions on a director's competitive activities. It includes details about the resolution date, the director involved, and the voting results. The content is a formal announcement of a board/management related decision rather than a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a report publication or certification. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management-related disclosure, confirming this classification.
2021-08-31 Chinese
公告本公司110年股東常會重要決議事項
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement from a company (1795 美時) regarding the important resolutions made at its Annual General Meeting (股東常會) held on 110/08/31 (Taiwanese calendar year). The content includes approval of earnings distribution, approval of the business report and financial statements for the previous fiscal year, amendments to procedures, and lifting of director competition restrictions. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official results from shareholder votes at a general meeting. The document length is short and it is not the full report itself but the announcement of the meeting's resolutions. Therefore, the correct classification is DVA with high confidence.
2021-08-31 Chinese
公告本公司董事會決議買回庫藏股轉讓予員工
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from the company's board regarding a decision to repurchase treasury shares for transfer to employees. It details the buyback plan, including the number of shares, price range, purpose, and procedures. It also includes the board's statement on the financial impact and an assessment from a securities underwriter on the reasonableness of the buyback price. The document is not a financial report or earnings release but an update on a capital action involving share repurchase and transfer to employees. The document length is 3276 characters, which is relatively short and focused on a specific capital transaction. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance).
2021-08-24 Chinese
110年7月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company, 美時, providing information on loan balances and endorsement guarantees for the current and previous months. It contains tabulated data on financial guarantees and intercompany endorsements but does not include comprehensive financial statements or detailed analysis. The document length is only 619 characters, indicating it is a short announcement rather than a full report. There is no indication of an annual or interim report, audit report, or earnings release. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement providing specific financial information without constituting a full financial report or other specialized filing.
2021-08-20 Chinese
110年7月營業收入
Regulatory Filings Classification · 95% confidence The document is a summary report of monthly and cumulative operating revenue figures for a company named 美時, presented in a tabular format with explanations about accounting standards and reporting practices. It contains no detailed financial statements, management discussion, or comprehensive analysis. The length is short (779 characters), and it appears to be a regulatory disclosure of revenue figures rather than a full financial report. There is no indication that this is an announcement of a report publication or a certification. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement of financial data without the depth of an interim or annual report.
2021-08-20 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.